Skip to content

Farma & Fit: value indication

Roughly what is an SME worth on what it filed? A range from its adjusted equity and its earnings, with your own assumptions, recalculated as you go.

Value indication

Farma & Fit

BE 1016.864.460
NACE 47.730, Retail sale of pharmaceutical products
latest balance sheet 31-12-2025indication, not a valuation or advice

Indicative value of the equity

Indication, not a valuation or advice
€174,013 to €234,631

Midpoint €199,270 · 50% capitalised earnings, 50% adjusted equity

Adjusted equity €44,933
Capitalised earnings €303,093 to €424,330
Indication €174,013 to €234,631

Your assumptions

Capitalised earnings
%

The return a buyer expects on the money put in. Higher for more risk. The range also computes with 2 points more and less.

Adjust the equity
Blend
50%
Optional: your own multiple

Checked holds no market prices, so it suggests no multiple. If you have one from a transaction or a study, the tool applies it to the filed EBITDA less the net financial debt.

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€44,933
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€44,933

Capitalised earnings

net result for the year (9904)
2025
€42,433
Average result
€42,433
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€303,093 / €353,608 / €424,330

What this indication leaves out

  • Market prices and comparable transactions: Checked does not hold them.
  • Anything after the latest accounts, and items off the balance sheet (guarantees, leases, disputes).
  • The real value of buildings, stock and receivables: enter your own revaluation or adjustment.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale.

For a valuation to decide on: a company auditor or a certified accountant.

Source: filed annual accounts (NBB), latest balance sheet at 31 December 2025. Prepared on 28 September 2026 via checked.be. Indication, not a valuation or advice.